Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 754 across all filing types
Latest filing 2023-06-02 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
关于作废处理2022年限制性股票激励计划部分限制性股票的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company regarding the cancellation of part of its 2022 restricted stock incentive plan. It details board and supervisory meetings, approvals, and legal opinions related to the stock incentive plan and the cancellation of certain restricted shares. The document does not contain financial statements or detailed financial performance data, nor is it a transcript, presentation, or report. It is a formal announcement about a corporate action related to stock incentives, specifically the cancellation of restricted stock. This fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement about corporate governance and stock incentive plan adjustments but not a full management report or financial report.
2023-06-02 Chinese
关于公司2022年限制性股票激励计划首次授予部分第一个归属期归属条件成就的公告
Remuneration Information Classification · 95% confidence The document is a detailed announcement regarding the company's 2022 restricted stock incentive plan, specifically about the first vesting period conditions being met and the corresponding stock vesting for eligible employees. It includes information on the stock grant, vesting conditions, performance targets, approval procedures, legal opinions, and lists of beneficiaries. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is also not a regulatory filing or certification. The content focuses on the stock incentive plan implementation and vesting results, which is a form of remuneration information related to executive and employee compensation. Therefore, the document best fits the category of Remuneration Information (DEF 14A).
2023-06-02 Chinese
关于实际控制人兼董事长增持股份计划实施进展的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of a share increase plan by the company's actual controller and chairman. It details the number of shares purchased, the amount spent, and the ongoing nature of the share increase plan. The document does not contain financial statements or detailed financial analysis but rather reports on a specific transaction involving the company's shares by a director. This fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company or its directors buying back or increasing their own shares. The document length is short and focused solely on this share transaction progress, confirming it is not a full financial report or other type of filing.
2023-05-29 Chinese
大华会计师事务所（特殊普通合伙）关于对科兴生物制药股份有限公司 2022 年年报问询函的回复
Audit Report / Information Classification · 95% confidence The document is a detailed response from Da Hua Certified Public Accountants to an inquiry letter from the Shanghai Stock Exchange regarding the 2022 annual report of科兴生物制药股份有限公司. It addresses specific accounting treatments, financial data, audit procedures, and compliance with accounting standards related to the 2022 annual report. The document includes detailed financial explanations, audit procedures, and conclusions about the company's 2022 annual financial statements. It is not the annual report itself but a formal audit/investigation response related to the annual report. Given the nature of the document as an audit inquiry response focusing on accounting principles, audit procedures, and verification of financial data, it fits best under the category of Audit Report / Information (AR). The document length (13,838 characters) and content confirm it is a substantive audit-related report rather than a brief announcement or certification. Therefore, the classification is AR with high confidence. FY 2022
2023-05-24 Chinese
2022年年度报告（更新后）
Annual Report Classification · 100% confidence The document is titled '2022 年年度报告' which translates to '2022 Annual Report'. It contains detailed financial data, management discussion and analysis, company overview, risk factors, governance, and audited financial statements. The document length is substantial (15,000 characters) and includes comprehensive financial and operational information for the full fiscal year 2022. It also includes signatures from company officers and auditors, and detailed sections typical of an annual report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-05-24 Chinese
中信建投证券股份有限公司关于科兴生物制药股份有限公司2022年年报问询函回复的核查意见
Annual Report Classification · 95% confidence The document is a detailed response to an inquiry letter from the Shanghai Stock Exchange regarding the 2022 annual report of 科兴生物制药股份有限公司 (Kexing Biopharmaceutical Co., Ltd.). It contains extensive financial data, including revenue, profit, sales breakdown by region and product, customer information, cost structure, and fixed asset details for the year 2022. The document also includes analysis and explanations related to the company's 2022 operating performance, sales expenses, and asset growth. The presence of comprehensive financial figures, management explanations, and detailed operational data indicates this is a substantive financial report rather than a brief announcement or certification. The document is clearly related to the full-year financial performance and business activities for 2022, matching the characteristics of an Annual Report (10-K). FY 2022
2023-05-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.